Precision medicine

EQS-News: Evotec receives € 150 m loan from European Investment Bank

Retrieved on: 
Sunday, February 12, 2023
ISIN, European Investment Bank, EIB, EQUITY, CORE, Therapy, Precision medicine, EVO, Frankfurt Stock Exchange, Disease, MDAX, Biotechnology, Medication, Research, Security (finance), Renewable energy, Pharmaceutical industry, Bank, Fine chemical, Evotec, EU

As a life science company focused on research, development, and manufacturing of novel precision medicines, Evotec aims to create global access to first- and best-in-class therapeutics.

Key Points: 
  • As a life science company focused on research, development, and manufacturing of novel precision medicines, Evotec aims to create global access to first- and best-in-class therapeutics.
  • Evotec will use the financing to fund its internal R&D activities, equity investments, as well as the new biologics manufacturing facility, J.POD® Toulouse, France (EU).
  • The EIB financing will enable Evotec to further broaden its portfolio, which currently spans more than 90 active projects across more than 30 companies worldwide.
  • J.POD® Toulouse, France (EU) is the second facility of its kind and the first one on European ground.

Prometheus Biosciences to Present at the SVB Securities Global Biopharma Conference

Retrieved on: 
Thursday, February 9, 2023
Conference, Precision medicine, SAN, Therapy, Event, Pharmaceutical industry, Broadcasting

SAN DIEGO, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc .

Key Points: 
  • SAN DIEGO, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc .
  • (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutics for the treatment of immune-mediated diseases, today announced that management will conduct a fireside chat at the SVB Securities Global Biopharma Conference on February 14, 2023 at 12:00 PM ET.
  • A live and archived webcast of the fireside chat will be available via the Events & Webcasts page on the Investor section of the Prometheus Biosciences website.

Myriad Genetics to Participate in Upcoming Healthcare Conferences

Retrieved on: 
Thursday, February 9, 2023
Conference, Genetic testing, Precision medicine, MYGN, SALT, Association for Molecular Pathology v. Myriad Genetics, Inc., Genetics, Digital health, Pharmaceutical industry

SALT LAKE CITY, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced management will participate at the upcoming healthcare conferences.

Key Points: 
  • SALT LAKE CITY, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced management will participate at the upcoming healthcare conferences.
  • The BTIG MedTech, Digital Health, Life Sciences and Diagnostic Tools Conference on Feb. 14, 2023.
  • The 44th Annual Raymond James & Associates Institutional Investors Conference with a presentation on March 6, 2023, at 11:35 a.m.
  • The 43rd Annual Cowen Health Care Conference with a presentation on March 7, 2023, at 10:30 a.m.

Anavex Life Sciences Reports Fiscal 2023 First Quarter Financial Results

Retrieved on: 
Tuesday, February 7, 2023
Disease, EDGAR, Research, Clinical trial, Neurodegeneration, Rett syndrome, CNS, Cognition, Conference call, Congress, Therapy, ADAS-Cog, Webcast, Publication, Conference, Coronavirus Scientific Advisory Board (Turkey), Central nervous system, Drug development, Patient, Society, SIGMAR1, Dementia, Precision medicine, Office of the National Coordinator for Health Information Technology, Nature, Data, Doctor of Philosophy, Broadcasting, Pharmaceutical industry, Video game, MD

NEW YORK, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today reported financial results for its fiscal quarter ended December 31, 2022.

Key Points: 
  • Company expects to announce topline results from this study in the second half of 2023.
  • On January 12th, 2023, Anavex presented at the 41st Annual J.P. Morgan Healthcare Conference, in San Francisco, CA.
  • General and administrative expenses for the quarter of $3.3 million compared to $3.1 million for the comparable quarter of fiscal 2022.
  • Research and development expenses for the quarter of $12.1 million compared to $8.7 million for the comparable quarter of fiscal 2022.

Syneos Health and Haystack Health Partner to Accelerate Clinical Trials with AI

Retrieved on: 
Tuesday, February 7, 2023
Privacy, Roger Hawkins (drummer), Hay, Natural language, Failure, Syneos Health, Natural language processing, Artificial intelligence, Health, Patient, Partnership, Precision medicine, NLP, Research, Pharmaceutical industry

The combined capabilities of Syneos Health and Haystack Health will more effectively and efficiently identify and match clinical trial opportunities for patients.

Key Points: 
  • The combined capabilities of Syneos Health and Haystack Health will more effectively and efficiently identify and match clinical trial opportunities for patients.
  • Initially, these new data solutions will only be available for Syneos Health sites in the US, with a focus on oncology and immunology.
  • Syneos Health and Haystack Health have been collaborating directly with sites and sponsors over several months.
  • Haystack Health offers an advanced solution leveraging AI to match patients to trials while preserving privacy,” said Baba Shetty, President, Technology & Data Solutions, Syneos Health.

AC Immune Awarded New Grants from MJFF and Target ALS Supporting Programs Targeting TDP-43

Retrieved on: 
Tuesday, February 7, 2023
Amyotrophic lateral sclerosis, Barrow Neurological Institute, Target, Alpha-synuclein, Disease, Research, Diagnosis, Neurodegeneration, Pathology, The Michael J. Fox Foundation, NDD, MJFF, Frontotemporal lobar degeneration, Precision medicine, International Center, PET, FTLD, Patient, Drug discovery, ALS, Kansas City University, National Center for Research Resources, Senior, AC, TAR, Engineering, Pharmaceutical industry, Medical imaging, Biotechnology

Fox Foundation for Parkinson’s Research (MJFF) and Target ALS Foundation (Target ALS) supporting research programs to enable diagnosis of TDP-43 (TAR DNA-binding protein 43), recognized as an important target in multiple neurodegenerative diseases (NDDs) such as amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD) and as a prominent co-pathology in Alzheimer’s and Parkinson’s diseases.

Key Points: 
  • Fox Foundation for Parkinson’s Research (MJFF) and Target ALS Foundation (Target ALS) supporting research programs to enable diagnosis of TDP-43 (TAR DNA-binding protein 43), recognized as an important target in multiple neurodegenerative diseases (NDDs) such as amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD) and as a prominent co-pathology in Alzheimer’s and Parkinson’s diseases.
  • Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: “It is an honor to have the support of MJFF and Target ALS, two leading international organizations that recognize the pressing need for diagnostics to detect pathological TDP-43.
  • AC Immune and its collaborators recently demonstrated their expertise in developing cutting-edge PET imaging agents by providing the first images of alpha-synuclein.
  • The development of a TDP-43 specific biofluid-based diagnostic test has the potential to more rapidly enable confirmed early diagnosis.”
    The MJFF and Target ALS grants collectively provide more than USD 500,000 in additional non-dilutive capital to support the advancement of diagnostic programs targeting TDP-43.

Ashvattha Therapeutics Announces First Patient Enrolled in a Phase 1 Study of [18F]OP-801 for Use as Imaging Agent

Retrieved on: 
Monday, February 6, 2023
Amyotrophic lateral sclerosis, Disease, Stanford University School of Medicine, Safety, HD, Trial of the century, Neuroinflammation, Pharmacokinetics, Microglia, CT, Neurodegeneration, Patient, HDT, Clinical trial, ALS, Precision medicine, Doctor of Philosophy, Brain, Therapy, Inflammation, Medical imaging

REDWOOD CITY, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company developing novel nanomedicines called hydroxyl dendrimer therapeutics (HDT), today announced that the first patient has been enrolled in a Phase 1/2 clinical study to evaluate the safety, pharmacokinetics and biodistribution of an intravenously administered dose of [18F]OP-801 in healthy volunteers and in patients with amyotrophic lateral sclerosis (ALS) (NCT05395624). [18F]OP-801 is a hydroxyl dendrimer (HD) imaging agent that selectively targets reactive macrophages and microglia – key markers of neuroinflammation.

Key Points: 
  • [18F]OP-801 is a hydroxyl dendrimer (HD) imaging agent that selectively targets reactive macrophages and microglia – key markers of neuroinflammation.
  • “The initiation of the clinical trial evaluating [18F]OP-801 as an imaging agent is a significant step to unlocking the potential of our proprietary HD technology for treatment of neurological diseases,” said Jeffrey Cleland, Ph.D., chairman, CEO and president of Ashvattha Therapeutics.
  • “With [18F]OP-801, we will be able to estimate HDT uptake in the diseased part of the brain prior to treating patients with the HDT.
  • The study will also measure the biodistribution and clearance of the HD imaging agent in both populations and evaluate the uptake of [18F]OP-801 in regions of neuroinflammation in ALS patients using PET/computed tomography (CT) scans.

Helsinn announces publication of new data evaluating impact of NEPA (netupitant/palonosetron) on hospital costs

Retrieved on: 
Friday, February 3, 2023
Vomiting, Palonosetron, Future Oncology, CINV, Nausea, Hospital, APON, Patient, Use, APPA, Precision medicine, NEPA, Degenerative disease, Research, Ondansetron, Medical imaging

The article, “Antiemetic Use and Chemotherapy Induced Nausea and Vomiting related Hospitalization Costs After Highly or Moderately Emetogenic Chemotherapy”, evaluates the effect of NEPA on chemotherapy-induced nausea and vomiting (CINV)-related hospitalization costs.

Key Points: 
  • The article, “Antiemetic Use and Chemotherapy Induced Nausea and Vomiting related Hospitalization Costs After Highly or Moderately Emetogenic Chemotherapy”, evaluates the effect of NEPA on chemotherapy-induced nausea and vomiting (CINV)-related hospitalization costs.
  • NEPA was compared to aprepitant/fosaprepitant-containing regimens among patients who received highly or moderately emetogenic chemotherapy in the US.
  • The study findings suggest that the downstream economic impact of antiemetic choice may differ depending on the combination of treatments.
  • Hospitalizations with CINV as the primary reason for admission were identified and all incurred costs for these hospital stays were used in the cost accounting.

GTG to form Strategic Alliance with global testing leader QIAGEN

Retrieved on: 
Wednesday, February 1, 2023
Health, Family medicine, Automation, Large intestine, DNA, ASX, Genetypes, Commercial Operating System (COS), Software, Authorization, Colorectal cancer, Accreditation, QIAGEN, DNA sequencing, NGS, Genomics, Patient, Partnership, NATA, GTG, Precision medicine, Growth, Organization, Fine chemical

MELBOURNE, Australia, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, “Company”, “GTG”), a global leader in guideline-driven genomics-based tests in health, wellness and serious diseases, is pleased to announce that the Company is forming a strategic alliance with QIAGEN, a global leader in molecular testing with operations in 35 countries.

Key Points: 
  • MELBOURNE, Australia, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, “Company”, “GTG”), a global leader in guideline-driven genomics-based tests in health, wellness and serious diseases, is pleased to announce that the Company is forming a strategic alliance with QIAGEN, a global leader in molecular testing with operations in 35 countries.
  • The partnership will further enhance GTG’s reputation as a regional leader in precision medicine in predicative and consumer genomics, utilizing QIAGEN technologies.
  • QIAGEN will support the Company through their global technical expertise and leadership, and work closely with GTG to bolster automation capability with hardware, reagents and panels, bringing best-in-class testing.
  • This strategic alliance will leverage QIAGEN testing technologies from Sample to Insight for multiple applications.

SomaLogic announces Certified Site expansion through world-class multiomics initiative with Group 42 Healthcare

Retrieved on: 
Tuesday, January 31, 2023
AI, KSA, Epitope, United Arab Emirates, Proteomics, Kingdom, CVS, Health, Intelligence, Partnership, Cleveland Clinic Abu Dhabi, SomaLogic, Precision medicine, Cleveland, Cros, Plasma, Research, Fine chemical, Pharmaceutical industry, G42

BOULDER, Colo., Jan. 31, 2023 (GLOBE NEWSWIRE) -- SomaLogic (NASDAQ: SLGC), a leader in data-driven proteomics technology, today announced the expansion of its SomaLogic™ Certified Site program through a recently-launched, world-class proteomics initiative with Group 42 Healthcare (G42), an artificial intelligence and cloud computing company.

Key Points: 
  • BOULDER, Colo., Jan. 31, 2023 (GLOBE NEWSWIRE) -- SomaLogic (NASDAQ: SLGC), a leader in data-driven proteomics technology, today announced the expansion of its SomaLogic™ Certified Site program through a recently-launched, world-class proteomics initiative with Group 42 Healthcare (G42), an artificial intelligence and cloud computing company.
  • As part of the agreement between the two entities G42 will be the first certified site in the Middle East.
  • The SomaLogic Certified Site program gives labs and institutions—including academia and contract research organizations (CROs)—access to the SomaScan Assay, with more than 7,000 protein measurements per sample and up to 90 samples per assay kit.
  • SomaLogic can run approximately 7,000 protein measurements on a single 55 microliter plasma or serum sample.